The use of genetically engineered cells for assessing CYP2D6-related polymorphic effects.

This publication has 6 references indexed in Scilit:

• The Decreased in Vivo Clearance of CYP2D6 Substrates by CYP2D6*10 Might Be Caused Not Only by the Low-Expression but Also by Low Affinity of CYP2D6
  Archives of Biochemistry and Biophysics, 2000
• Novel Approach To Predicting P450-Mediated Drug Metabolism: Development of a Combined Protein and Pharmacophore Model for CYP2D6
  Journal of Medicinal Chemistry, 1999
• Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs.
  Cancer Chemotherapy and Pharmacology, 1999
• Genetic Polymorphisms of HumanN-Acetyltransferase, Cytochrome P450, Glutathione-S-Transferase, and Epoxide Hydrolase Enzymes: Relevance to Xenobiotic Metabolism and Toxicity
  Critical Reviews in Toxicology, 1999
• Preclinical Drug Metabolism in the Age of High-Throughput Screening: An Industrial Perspective
  Pharmaceutical Research, 1997
• High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver
  Analytical Biochemistry, 1987